SEC
SEC Paid $50M+ to One Whistleblower for Early Enforcement Tip
The SEC paid one whistleblower $50M+ for an early tip that triggered an enforcement action, implying at least $167M in underlying sanctions.
Latest — Page 23
Deals
Lilly Bets on Orexins, Tirzepatide Playbook Repeats
Eli Lilly acquires into the orexin drug class, betting the maturing CNS mechanism follows the same multi-indication arc as GLP-1.
FDA
Novo Nordisk's 7.2 mg Wegovy Hits US Shelves at Triple the Standard Dose
Novo Nordisk's 7.2 mg Wegovy is now available in the US, tripling the standard 2.4 mg dose in a direct bid to reclaim ground lost to Lilly's Zepbound.
Deals
Digital Health Posts $4B Q1 Record as 12 Deals Take 59%
Digital health hit $4B in Q1 2026, up $1B year-over-year, but 12 mega-deals claimed 59% of all capital as total deal count fell to 110.
FDA
TrumpRx Lists AbbVie's Humira at $950/Month Next to Cheaper Biosimilars
White House added Humira to TrumpRx at $950/month, the same site that already lists cheaper Pfizer and Amgen biosimilars.
FDA
Amgen's Tepezza Just Got Injectable Data. So Did Viridian.
Amgen's subcutaneous Tepezza cleared Phase 3 as Viridian Therapeutics competes in the same thyroid eye disease market. Both are racing to file with FDA.
FDA
FDA Asks Congress for Market Withdrawal Power Over Manufacturing Gaps
FDA's April 3 budget proposal asks Congress for market withdrawal power over postapproval manufacturing gaps and API supplier non-disclosure.
FDA
Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor
Sanofi's lunsekimig cleared asthma and nasal polyp trials but failed its eczema Phase 2, leaving Dupixent without a clear successor as its patent cliff nears.
Deals
Apnimed Locks $150M Credit Line for AD109 Sleep Apnea Launch
Apnimed secured up to $150M from HCRx to launch AD109, with only $50M unconditional and the rest tied to FDA approval and a sales milestone.
Deals
Gilead Pays $3.15B for Tubulis in Third ADC Bet of 2026
Gilead's $3.15B upfront buy of Tubulis adds a 59%-ORR NaPi2b ADC to its pipeline — its third acquisition of 2026, totaling over $12B spent.
FDA
ImmunityBio Loses $2B in a Day After FDA Hits 'Cures Cancer' Pitch
FDA warned ImmunityBio after Chairman Patrick Soon-Shiong said Anktiva could 'cure cancer' on a podcast. Stock dropped 21%, $2B market cap gone.
Deals
Lilly Pays $7.8B for Centessa to Buy Into the Orexin Race
Lilly is paying $7.8B for Centessa — $38/share plus a $9 CVR — to grab cleminorexton, a Phase IIa orexin agonist for narcolepsy.
deals
Deals
Takeda Files WARN for 634 US Cuts, 247 of Them at Cambridge HQ
Takeda filed a WARN notice to cut 634 US jobs, with 247 hitting its Cambridge headquarters — the largest concentration in the restructuring.
Deals
Syneron Bio Closes $150M Series B for Peptides
Syneron Bio raised a $150M Series B for peptide development. GLP-1s proved the format can print billions. The program list is still a mystery.
FDA
Makary's FDA Gets White House Backing to Fast-Track US Biotech vs. China
White House budget backs FDA policy shifts under Makary to speed US clinical trials and cut costs — framed as a direct counter to China's biotech ambitions.
